Worst case scenario.

Re: the above, you may have wondered, “Ok, but did any of these excess breast cancers actually impact mortality?” The Million Women Study from the U.K. contributed a large amount of data to the above collaborative study. It began in 1998 as a prospective population-based study of outcomes following MHT and separately reports 20-year breast cancer mortality among nearly 1,000,000 post-menopausal women enrolled, one-third of whom were taking MHT when they enrolled and another 15% previously. Alas, these women with a history of MHT saw a significant increase in breast cancer mortality over the next 20 years. While the increased risk was seen across all groups, women taking combination MHT for over 5 years had a particularly increased risk. TBL: The excess breast cancers associated with prolonged combination menopausal hormone replacement are also associated with an increased risk of breast cancer mortality. | Beral, Lancet 2019